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Aim
To evaluate the 5-yr use of 2 anti-TNF preparations,
Etanercept (ET) and Adalimumab (AD), in children with
refractory to conventional treament JIA.
Patients-methods
The safety and efficacy of ET and AD were assessed in 46
children aged 2–16 yrs. 32/46 received ET and 14 AD
together with a DMARD (45/46), mainly methotrexate,
and prednisone (22/46). All pts were assessed clinicaly,
cardiologicaly, hematologicaly, biochemicaly and immu-
nologicaly pre- and every 3–6 mo port-treatment. Efficacy
was assessed by the application of ACRped criteria.
Results
Safety: Common respiratory tract infections were
recorded in 28% of pts (10/34 under ET and 3/14 under
AD). Serious infections were recorded in 4.7% (1 ET, 1
AD). No other serious adverse effects were recorded. Effi-
cacy: ACRped 50–70. 1 st yr: 88% of the ET and 68% of
the AD group. 2 nd yr: 81% of the ET and 66.7% of the AD
group. 3 yr: 83% of the ET and 100% of the AD group.
During the 5-yr period, 11/46 pts (28%) switched from ET
to AD or vice versa. Of all patients, 32.5% discontinued
anti-TNF treatment due to remission and 52.2% had a sat-
isfactory response (ACRped 50–70), while 8.7% had a
poor response either to ET or AD.
Conclusion
Most of the patients with refractory to conventional treat-
ment JIA respond satisfactorily to the long-term adminis-
tration of anti-TNFs. The first 2 years are critical to predict
a good and sustained response. Although serious infec-
tions are rare, a systematic vigilance is warranted in order
to avoid fatal outcomes.
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